SK10612001A3 - Spôsob výroby riadene biodegradovateľných keramických vlákien z hydrosólu oxidu kremičitého - Google Patents
Spôsob výroby riadene biodegradovateľných keramických vlákien z hydrosólu oxidu kremičitého Download PDFInfo
- Publication number
- SK10612001A3 SK10612001A3 SK1061-2001A SK10612001A SK10612001A3 SK 10612001 A3 SK10612001 A3 SK 10612001A3 SK 10612001 A SK10612001 A SK 10612001A SK 10612001 A3 SK10612001 A3 SK 10612001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- hydrosol
- viscosity
- silica
- spinning
- mpas
- Prior art date
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 171
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 82
- 239000000919 ceramic Substances 0.000 title claims description 21
- 238000009987 spinning Methods 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000013543 active substance Substances 0.000 claims abstract description 20
- 239000000835 fiber Substances 0.000 claims description 128
- 238000006065 biodegradation reaction Methods 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 abstract description 3
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 230000032683 aging Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 18
- 101000988229 Homo sapiens Protocadherin gamma-A12 Proteins 0.000 description 17
- 102100029264 Protocadherin gamma-A12 Human genes 0.000 description 17
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 229910052710 silicon Inorganic materials 0.000 description 11
- 239000010703 silicon Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- VPNGEIHDPSLNMU-MERQFXBCSA-N dexmedetomidine hydrochloride Chemical compound Cl.C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CNC=N1 VPNGEIHDPSLNMU-MERQFXBCSA-N 0.000 description 8
- 229960002746 dexmedetomidine hydrochloride Drugs 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 238000002411 thermogravimetry Methods 0.000 description 8
- 101000602015 Homo sapiens Protocadherin gamma-B4 Proteins 0.000 description 7
- 102100037554 Protocadherin gamma-B4 Human genes 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 101001072237 Homo sapiens Protocadherin-16 Proteins 0.000 description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 238000000578 dry spinning Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 102100029526 rRNA 2'-O-methyltransferase fibrillarin Human genes 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008131 herbal destillate Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- -1 silica alkoxide Chemical class 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- OXYOLJGIYXSJHS-UHFFFAOYSA-N 5-(5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole;hydrochloride Chemical compound Cl.C1C2=CC(F)=CC=C2CC1C1=CNC=N1 OXYOLJGIYXSJHS-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 229910002808 Si–O–Si Inorganic materials 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- AHDSRXYHVZECER-UHFFFAOYSA-N 2,4,6-tris[(dimethylamino)methyl]phenol Chemical compound CN(C)CC1=CC(CN(C)C)=C(O)C(CN(C)C)=C1 AHDSRXYHVZECER-UHFFFAOYSA-N 0.000 description 1
- RXCMFQDTWCCLBL-UHFFFAOYSA-N 4-amino-3-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(N)=C(O)C=C(S(O)(=O)=O)C2=C1 RXCMFQDTWCCLBL-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 101150008840 FDB3 gene Proteins 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233803 Nypa Species 0.000 description 1
- 235000005305 Nypa fruticans Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 229910020175 SiOH Inorganic materials 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229950007611 elcometrine Drugs 0.000 description 1
- CKFBRGLGTWAVLG-GOMYTPFNSA-N elcometrine Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 CKFBRGLGTWAVLG-GOMYTPFNSA-N 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- CUHVIMMYOGQXCV-LLVKDONJSA-N levomedetomidine Chemical compound C1([C@H](C)C=2C(=C(C)C=CC=2)C)=CNC=N1 CUHVIMMYOGQXCV-LLVKDONJSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- CUHVIMMYOGQXCV-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 CUHVIMMYOGQXCV-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229960003678 selegiline hydrochloride Drugs 0.000 description 1
- 229910002028 silica xerogel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000012686 silicon precursor Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
- C03B37/00—Manufacture or treatment of flakes, fibres, or filaments from softened glass, minerals, or slags
- C03B37/01—Manufacture of glass fibres or filaments
- C03B37/011—Manufacture of glass fibres or filaments starting from a liquid phase reaction process, e.g. through a gel phase
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C13/00—Fibre or filament compositions
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/62227—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres
- C04B35/62231—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres based on oxide ceramics
- C04B35/6224—Fibres based on silica
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2213/00—Glass fibres or filaments
- C03C2213/02—Biodegradable glass fibres
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Geochemistry & Mineralogy (AREA)
- Ceramic Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Inorganic Fibers (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Silicon Compounds (AREA)
- Colloid Chemistry (AREA)
- Artificial Filaments (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12118099P | 1999-02-22 | 1999-02-22 | |
PCT/FI2000/000131 WO2000050349A2 (en) | 1999-02-22 | 2000-02-21 | Biodegradable ceramic fibres from silica sols |
Publications (1)
Publication Number | Publication Date |
---|---|
SK10612001A3 true SK10612001A3 (sk) | 2002-02-05 |
Family
ID=22395079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1061-2001A SK10612001A3 (sk) | 1999-02-22 | 2000-02-21 | Spôsob výroby riadene biodegradovateľných keramických vlákien z hydrosólu oxidu kremičitého |
Country Status (15)
Country | Link |
---|---|
US (1) | US7897166B1 (cs) |
EP (1) | EP1144323B1 (cs) |
JP (1) | JP4932992B2 (cs) |
AT (1) | ATE368011T1 (cs) |
AU (1) | AU764663C (cs) |
CA (1) | CA2359699C (cs) |
CZ (1) | CZ20012748A3 (cs) |
DE (1) | DE60035672T2 (cs) |
ES (1) | ES2290013T3 (cs) |
HU (1) | HUP0200277A3 (cs) |
NO (1) | NO20014014D0 (cs) |
NZ (1) | NZ513013A (cs) |
PL (1) | PL204627B1 (cs) |
SK (1) | SK10612001A3 (cs) |
WO (1) | WO2000050349A2 (cs) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI19991806A (fi) * | 1999-08-25 | 2001-02-26 | Yli Urpo Antti | Uusia koostumuksia biologisesti aktiivisen aineen säädettyyn vapauttamiseen, ja niiden valmistus |
AUPQ573300A0 (en) | 2000-02-21 | 2000-03-16 | Australian Nuclear Science & Technology Organisation | Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use |
KR20070001145A (ko) | 2004-02-27 | 2007-01-03 | 델시테크 오와이 | 조정가능한 생체 재흡수성의 졸-겔 유도 이산화규소를제조하기 위한 방법 |
JP5554923B2 (ja) * | 2005-11-10 | 2014-07-23 | ザ・モーガン・クルーシブル・カンパニー・ピーエルシー | 高温耐熱繊維 |
US8455088B2 (en) * | 2005-12-23 | 2013-06-04 | Boston Scientific Scimed, Inc. | Spun nanofiber, medical devices, and methods |
WO2007135224A2 (en) | 2006-05-23 | 2007-11-29 | Delsitech Oy | Method for storing silica-based material, package produced with the method and use of package for packaging of silica-based products |
JP2010505883A (ja) | 2006-10-12 | 2010-02-25 | ザ ユニバーシティー オブ クイーンズランド | 免疫応答を調節するための組成物および方法 |
DE102007061873A1 (de) * | 2007-01-15 | 2008-07-17 | Bayer Innovation Gmbh | Kieselsol-Material zur Herstellung von biologisch degradierbaren und/oder resorbierbaren Kieselgel-Materialien dessen Herstellung und Verwendung |
DE102007026043B4 (de) * | 2007-06-04 | 2018-08-16 | Jiangsu Synecoun Medical Technology Co., Ltd. | Nicht-toxisches Polyethoxysiloxan-Material zur Herstellung von biologisch resorbierbares und/oder bioaktives Polyethoxysiloxan-Material enthaltenden Artikeln, dessen Herstellung und Verwendung |
DE102007061874A1 (de) * | 2007-12-19 | 2009-06-25 | Bayer Innovation Gmbh | Nicht-toxisches Polysiloxan-Material zur Herstellung von biologisch resorbierbaren und/oder bioaktiven Polysiloxan-Material enthaltenden Artikeln, dessen Herstellung und Verwendung |
DE102008033327A1 (de) * | 2008-07-16 | 2010-01-21 | Bayer Innovation Gmbh | Kieselsol-Material mit mindestens einem therapeutisch aktiven Wirkstoff zur Herstellung von biologisch degradierbaren und/oder resorbierbaren Kieselgel-Materialien für die Humanmedizin und/oder Medizintechnik |
WO2012058715A1 (en) | 2010-11-01 | 2012-05-10 | University Of Technology, Sydney | Immune-modulating agents and uses therefor |
WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
DE102015101282A1 (de) | 2015-01-29 | 2016-08-04 | Rwth Aachen | Verfahren und Vorrichtung zur Herstellung anorganischer Aerogel-Fasern |
FI20155779A (fi) | 2015-10-30 | 2017-05-01 | Solani Therapeutics Ltd | Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu |
CA3095574A1 (en) * | 2018-04-02 | 2019-10-10 | American Nano, LLC | Topical compositions incorporating silica fibers |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8401912A (nl) * | 1984-06-15 | 1986-01-02 | Tno | Met aktieve stof beladen biodegradeerbare polymeersubstraten, geschikt voor het gecontroleerd afgeven van de aktieve stof door middel van een membraan. |
US4895709A (en) | 1985-04-26 | 1990-01-23 | Sri International | Method of preparing metal carbides, nitrides, and the like |
EP0253554A3 (en) | 1986-07-15 | 1988-07-20 | Pfizer Inc. | Controlled release drug-containing fibers |
IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
JPH02124734A (ja) * | 1988-10-31 | 1990-05-14 | Nippon Sheet Glass Co Ltd | 無機繊維の製造方法 |
US4919871A (en) * | 1989-01-04 | 1990-04-24 | Ppg Industries, Inc. | Forming glass fibers from sol-gel compositions |
JPH02221417A (ja) * | 1989-01-04 | 1990-09-04 | Ppg Ind Inc | ゾル・ゲル組成物からの無機酸化物繊維の製造方法及びその装置 |
DE69105958T2 (de) | 1990-03-07 | 1995-08-10 | Joseph Davidovits | Verfahren zur herstellung eines aluminiumsilicat-geopolymers und danach hergestellte produkte. |
WO1995028124A2 (en) * | 1994-04-08 | 1995-10-26 | Atrix Laboratories, Inc. | An adjunctive polymer system for use with medical device |
WO1996014454A2 (en) * | 1994-11-08 | 1996-05-17 | Rockwool International A/S | Man-made vitreous fibres |
DE19609551C1 (de) * | 1996-03-12 | 1997-07-17 | Fraunhofer Ges Forschung | Biologisch degradierbare und/oder biologisch resorbierbare (Endlos)Fasern, Verfahren zu deren Herstellung und deren Verwendung als Verstärkungsfasern |
ATE301102T1 (de) * | 1996-05-29 | 2005-08-15 | Delsitech Oy | Lösliche oxide für biologische anwendungen |
US6632412B2 (en) * | 1999-12-01 | 2003-10-14 | Timo Peltola | Bioactive sol-gel derived silica fibers and methods for their preparation |
-
2000
- 2000-02-21 CZ CZ20012748A patent/CZ20012748A3/cs unknown
- 2000-02-21 ES ES00906390T patent/ES2290013T3/es not_active Expired - Lifetime
- 2000-02-21 AT AT00906390T patent/ATE368011T1/de active
- 2000-02-21 CA CA002359699A patent/CA2359699C/en not_active Expired - Fee Related
- 2000-02-21 SK SK1061-2001A patent/SK10612001A3/sk unknown
- 2000-02-21 NZ NZ513013A patent/NZ513013A/xx unknown
- 2000-02-21 HU HU0200277A patent/HUP0200277A3/hu unknown
- 2000-02-21 EP EP00906390A patent/EP1144323B1/en not_active Expired - Lifetime
- 2000-02-21 WO PCT/FI2000/000131 patent/WO2000050349A2/en active IP Right Grant
- 2000-02-21 DE DE60035672T patent/DE60035672T2/de not_active Expired - Lifetime
- 2000-02-21 PL PL350576A patent/PL204627B1/pl unknown
- 2000-02-21 AU AU28076/00A patent/AU764663C/en not_active Expired
- 2000-02-21 JP JP2000600935A patent/JP4932992B2/ja not_active Expired - Fee Related
- 2000-02-21 US US09/913,643 patent/US7897166B1/en not_active Expired - Lifetime
-
2001
- 2001-08-17 NO NO20014014A patent/NO20014014D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1144323B1 (en) | 2007-07-25 |
DE60035672D1 (de) | 2007-09-06 |
PL350576A1 (en) | 2002-12-30 |
NZ513013A (en) | 2002-11-26 |
CZ20012748A3 (cs) | 2002-03-13 |
HUP0200277A3 (en) | 2004-03-29 |
JP2002537502A (ja) | 2002-11-05 |
JP4932992B2 (ja) | 2012-05-16 |
AU2807600A (en) | 2000-09-14 |
HUP0200277A2 (hu) | 2002-05-29 |
ES2290013T3 (es) | 2008-02-16 |
WO2000050349A3 (en) | 2001-08-02 |
AU764663C (en) | 2005-02-03 |
AU764663B2 (en) | 2003-08-28 |
US7897166B1 (en) | 2011-03-01 |
NO20014014L (no) | 2001-08-17 |
CA2359699C (en) | 2009-08-11 |
DE60035672T2 (de) | 2008-04-30 |
ATE368011T1 (de) | 2007-08-15 |
WO2000050349A2 (en) | 2000-08-31 |
PL204627B1 (pl) | 2010-01-29 |
EP1144323A2 (en) | 2001-10-17 |
NO20014014D0 (no) | 2001-08-17 |
CA2359699A1 (en) | 2000-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2208582C2 (ru) | Средство для доставки, обеспечивающее непрерывное и/или регулируемое высвобождение биологически активных агентов | |
SK10612001A3 (sk) | Spôsob výroby riadene biodegradovateľných keramických vlákien z hydrosólu oxidu kremičitého | |
US7326422B2 (en) | Dissolvable oxides for biological applications | |
Wang et al. | Preparation of hollow hydroxyapatite microspheres | |
US9051204B2 (en) | Nontoxic polysiloxane material for producing biologically resorbable and/or bioactive articles containing polysiloxane material, its production and use | |
US10149825B2 (en) | Method for preparing adjustably bioresorbable sol-gel derived SiO2 | |
CN101259277A (zh) | 一种新型的骨科药物载体***及其制备方法 | |
Qu et al. | 4.428. Sol-Gel Processed Oxide Controlled Release Materials | |
CN112540051A (zh) | 介孔二氧化硅-聚乙烯醇水凝胶缓释贴剂的制备与应用 |